. . . . . . "approved"@en . "Humans and other mammals"@en . . . . . . . . . . . . . . "Prednicarbate"@en . . . . . . "For the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses."@en . . . . . . "Absorbed systemically across the stratum corneum."@en . . . . . "# Gupta AK, Chow M: A review of prednicarbate (Dermatop). Skin Therapy Lett. 2004 Dec-2005 Jan;9(10):5-6, 9. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/ 15657633"@en . . " "@en . . . . . . . "Prednicarbate is a relatively new topical corticosteroid drug. It is similar in potency to hydrocortisone. It is used in the treatment of inflammatory skin diseases, such as atopic dermatitis. It has a favorable benefit-risk ratio, with an inflammatory action similar to that of a medium potency corticosteroid, but with a low potential to cause skin atrophy. The anti-inflammation action of corticosteroids is associated with the inhibition of the interleukin 1-alpha cytokine within keratinocytes. IL-1a is also found in fibroblasts, where it is responsible for proliferation, collagenase induction and IL-6 synthesis, which are related to skin thickness."@en . . . . . "In common with other topical corticosteroids, prednicarbate has anti-inflammatory, antipruritic, and vasoconstrictive properties. In general, the mechanism of the anti-inflammatory activity of topical steroids is unclear. However, corticosteroids are thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2."@en . . . . . "73771-04-7"@en . . . . . . . . . . . .